Introduction
============

Rabies is a preventable yet fatal disease that is responsible for approximately 59 000 deaths each year.[@R1] However, widespread underreporting of rabies cases means that the actual number of deaths is likely to be higher. Poor and rural populations are disproportionately affected, with the majority of deaths occurring in children younger than 15 years in Asia and Africa.[@R2] Ninety-nine per cent of human rabies cases result from dog bites and, once symptoms begin, the disease is almost invariably fatal.[@R3] Human rabies is preventable through canine vaccination to eliminate rabies at its source or by administering rabies vaccines and immunoglobulin following bites, scratches or saliva exposure from suspected rabid mammals (i.e. postexposure prophylaxis).[@R4]

Another preventive strategy is pre-exposure prophylaxis, which involves giving a series of intramuscular or intradermal injections of rabies vaccine to prime the immune system. This enables fast recall of memory immune responses once a person is re-exposed to the virus.[@R4] Moreover, people who have received pre-exposure prophylaxis require fewer doses of postexposure rabies vaccine and can be treated without rabies immunoglobulin, which is costly and difficult to procure.[@R4] Although preventing rabies in dogs is the most cost-effective way of preventing human rabies deaths, pre-exposure prophylaxis is valuable for people at a high disease risk,[@R5] particularly in areas where controlling disease in the animal reservoir is difficult or has not been implemented and in areas where access to postexposure prophylaxis and rabies immunoglobulin is unreliable or nonexistent. National pre-exposure prophylaxis programmes for high-risk populations have been implemented in Peru and the Philippines.[@R6]^,^[@R7]

In 2010, a World Health Organization (WHO) position paper on rabies vaccines called for studies on the feasibility, cost--effectiveness and long-term impact of incorporating vaccines derived from cell culture or embryonated eggs into immunization programmes for children where canine rabies is a public health problem.[@R5] The paper also made recommendations on pre-exposure prophylaxis regimens and on the frequency of booster vaccinations and serological surveillance for at-risk individuals, such as veterinarians. The aim of this study was to review the scientific literature published between 2007 and 2016, as well as field data, to assess the current use and cost--effectiveness of pre-exposure rabies prophylaxis (excluding travel vaccines), particularly in children and in high-risk settings, in the context of recommendations made in the 2010 WHO rabies vaccine position paper on pre-exposure prophylaxis and booster vaccine administration.

Methods
=======

Literature search
-----------------

Our literature review was intended as an update of the review of the evidence on pre-exposure prophylaxis carried out for the 2010 WHO rabies vaccine position paper. Our search was conducted according to preferred reporting items for systematic reviews and meta-analyses guidelines.[@R8] We searched the PubMed, Centre for Agriculture and Biosciences International, Cochrane Library and Web of Science databases for papers on pre-exposure rabies prophylaxis published between 2007 and 29 January 2016 ([Fig. 1](#F1){ref-type="fig"}) using the search string: "rabies" AND "pre-exposure" AND ("prophylaxis" OR "vaccin\*"). We started at 2007 to include studies published after completion of the review for the WHO position paper. Additional references were obtained from citations in relevant publications. We excluded studies that assessed: (i) postexposure prophylaxis only; or (ii) pre-exposure prophylaxis either occupationally or in travellers. As we considered the safety and immunogenicity of WHO-recommended vaccination regimens for pre-exposure prophylaxis to be well established, we also excluded papers that confirmed the efficacy of these regimens, unless they specifically assessed the safety and immunogenicity of pre-exposure prophylaxis in children or given in combination with other vaccines. We included any type of study, in any language and from any country that assessed: (i) pre-exposure prophylaxis in children; (ii) the cost--effectiveness of pre-exposure prophylaxis; (iii) accelerated or revised pre-exposure prophylaxis regimens; or (iv) booster vaccination recommendations. Studies that assessed the cost of pre-exposure prophylaxis and its use in children were included regardless of publication date.

![**Flowchart showing the selection of publications on pre-exposure rabies prophylaxis, 2007--2016**](BLT.16.173039-F1){#F1}

Field data
----------

We reviewed field data from completed and ongoing pre-exposure prophylaxis campaigns in Peru and the Philippines. In Peru, the campaigns targeted people living in remote areas who were at risk of contracting rabies from vampire bats, whereas in the Philippines they targeted children at risk of dog-transmitted rabies.

### Peru

In Peru, vampire bats are a common source of rabies: the life-time risk of a bat bite in rural Amazon basin populations is reported to be 41 to 88%.[@R9]^,^[@R10] Outbreak reports and responses are delayed by the remoteness of these populations and controlling rabies in the bat reservoir is challenging.[@R11] Following a rabies outbreak in 2011, Peru began a mass pre-exposure prophylaxis vaccination campaign that targeted people in Condorcanqui and Bagua Provinces at a high risk of rabies from vampire bats.[@R6] The risk was regarded as high in these provinces because: (i) bat bites were common; (ii) there was evidence of rabies in circulation; (iii) housing conditions increased vulnerability; (iv) protective measures among the population were lacking; (v) tools for vector control were lacking; and (vi) the remote location of villages delayed health service responses. The campaign involved administering three intramuscular doses of human diploid cell or purified Vero cell vaccine on days 0, 7 and 28. Villages were prioritized to receive the intervention by classifying their epidemiological risk using the following variables: (i) the endemicity of bat rabies; (ii) the number of human rabies cases within the previous 6 months; (iii) the number of livestock rabies cases within the previous 6 months; (iv) the frequency of vampire bat bites (where there was bite surveillance); (v) history of postexposure prophylaxis; and (vi) important, recent ecological changes, such as an increase in the population, a change in the feeding habits of vampire bats, illegal mining or deforestation. Among villages with a history of postexposure prophylaxis interventions, priority was given to those in which the intervention took place more than 1 year previously, those where a low percentage of the population had received postexposure prophylaxis and those close to the site of a recent outbreak or of documented circulation of the rabies virus.

### Philippines

In the Philippines, pre-exposure rabies prophylaxis is recommended as an additional intervention for high-risk individuals, such as children and people at occupational exposure. In 2007, the Philippine Government implemented a Department of Health recommendation that free routine pre-exposure prophylaxis should be provided for school children aged 5 to 14 years who are living in high-risk areas.[@R7]^,^[@R12] To be included an area had to have: (i) an incidence of human and canine rabies above the  national average; (ii) an incidence of animal bites above the  national average; (iii) no or low canine vaccination coverage, which was defined as less than  30% coverage of the estimated dog population; and (iv) limited access to postexposure prophylaxis, for example, due to geographical isolation, inadequate treatment facilities or poverty. Schoolchildren were targeted because almost 50% of all rabies exposure in the Philippines occurs in children younger than 15 years. Child deaths due to rabies are associated with poverty and, where postexposure prophylaxis is available, with limited or delayed access to health services. The rationale for pre-exposure prophylaxis was that it: (i) may protect children who do not receive postexposure prophylaxis, for example, after unremarked exposure (i.e. if their antibody titre at exposure is ≥ 0.5 IU/mL); (ii) may protect patients when postexposure prophylaxis is delayed; (iii) accelerates antibody responses to postexposure prophylaxis; and (iv) reduces the cost of postexposure prophylaxis by removing the need for rabies immunoglobulin and reducing the number of postexposure prophylaxis doses required from 8 to 2 ([Table 1](#T1){ref-type="table"}). The pre-exposure prophylaxis schedule consisted of administering three intradermal doses of purified Vero cell or chick embryo cell vaccine on days 0, 7 and 28.

###### Postexposure rabies prophylaxis regimens, by pre-exposure prophylaxis, the Philippines, 2007

  Exposure category^a^   Following pre-exposure rabies prophylaxis                Without pre-exposure rabies prophylaxis                                                               
  ---------------------- --------------------------------------------------- ---- ----------------------------------------- ----------------------------------------------------------- -----------------------------------------------
  Category II            1 intradermal dose on days 0 and 3 (i.e. 2 doses)   No                                             2 intradermal doses on days 0, 3, 7 and 28 (i.e. 8 doses)   No
  Category III           1 intradermal dose on days 0 and 3 (i.e. 2 doses)   No                                             2 intradermal doses on days 0, 3, 7 and 28 (i.e. 8 doses)   Yes, with the volume dependent on body weight

^a^ Category-II exposure is defined as nibbling of uncovered skin, minor scratches or abrasions without bleeding and category-III exposure, as single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats.[@R5]

Results
=======

The systematic review of the literature identified 31 publications on pre-exposure rabies prophylaxis that met inclusion criteria ([Table 2](#T2){ref-type="table"}).

###### Publications on pre-exposure rabies prophylaxis, systematic review of the literature, 2007--2016

  Reference                    Publication type   Publication date   Study location                              Prophylaxis                                                                                                                          Vaccinees
  ---------------------------- ------------------ ------------------ ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------
  Aikimbayev et al.[@R13]      Meeting report     2014               Middle East, Eastern Europe, Central Asia   N/A                                                                                                                                  Children and adults
  Banga et al.[@R14]           Journal article    2014               United States                               N/A                                                                                                                                  Adults
  Brown et al.[@R15]           Journal article    2011               United Kingdom                              N/A                                                                                                                                  Adults
  Brown et al.[@R16]           Journal article    2008               United Kingdom                              N/A                                                                                                                                  Adults
  Chulasugandha et al.[@R17]   Journal article    2006               Thailand                                    PVRV, PCECV                                                                                                                          Children
  Cunha et al.[@R18]           Journal article    2010               Brazil                                      PVRV, PCECV                                                                                                                          Adults
  Dodet et al.[@R19]           Meeting report     2009               Viet Nam                                    N/A                                                                                                                                  Children and adults
  Dodet[@R7]                   Meeting report     2010               Philippines                                 N/A                                                                                                                                  Children and adults
  Hampson et al.[@R1]          Journal article    2015               Worldwide                                   N/A                                                                                                                                  Children and adults
  Jelinek et al.[@R20]         Journal article    2015               Germany                                     PCECV, Japanese encephalitis vaccine                                                                                                 Adults
  Kamoltham et al.[@R21]       Journal article    2011               Thailand                                    PVRV                                                                                                                                 Children
  Kamoltham et al.[@R22]       Journal article    2007               Thailand                                    PCECV                                                                                                                                Children
  Khawplod et al.[@R23]        Journal article    2008               Thailand                                    PCECV, PVRV                                                                                                                          Adults
  Khawplod et al.[@R24]        Journal article    2012               Thailand                                    PCECV, PVRV                                                                                                                          Adults
  Khawplod et al.[@R25]        Journal article    2007               Thailand                                    PCECV, PVRV                                                                                                                          Adults
  Lang et al.[@R26]            Journal article    1997               Viet Nam                                    PVRV                                                                                                                                 Children
  Lang et al.[@R27]            Journal article    2009               Viet Nam                                    PVRV combined with vaccination against diphtheria, tetanus, pertussis (whole-cell vaccine) and poliomyelitis (inactivated vaccine)   Children
  Lau & Hohl[@R28]             Journal article    2013               Australia                                   PCECV                                                                                                                                Children and adults
  Lim & Barkham[@R29]          Journal article    2010               Singapore                                   PVRV                                                                                                                                 Adults
  Liu[@R30]                    Journal article    2012               Worldwide                                   N/A                                                                                                                                  Children
  Lumbiganon et al.[@R31]      Journal article    1989               Thailand                                    PCECV                                                                                                                                Children
  Malerczyk et al.[@R32]       Journal article    2013               Germany                                     PCECV                                                                                                                                Children
  Mills et al.[@R33]           Journal article    2011               Australia                                   HDCV                                                                                                                                 Children and adults
  Pengsaa et al.[@R34]         Journal article    2009               Thailand                                    PCECV combined with Japanese encephalitis vaccine                                                                                    Children
  Ravish et al.[@R35]          Journal article    2013               India                                       PCECV                                                                                                                                Children
  Shanbag et al.[@R36]         Journal article    2008               India                                       PVRV, PCECV                                                                                                                          Children
  Strady et al.[@R37]          Journal article    2009               France                                      HDCV, PVRV                                                                                                                           Children
  Sudarshan et al.[@R38]       Journal article    2011               Worldwide                                   N/A                                                                                                                                  Children and adults
  Vashishtha et al.[@R39]      Journal article    2014               India                                       N/A                                                                                                                                  Children
  Vien et al.[@R40]            Journal article    2008               Viet Nam                                    PVRV combined with vaccination against diphtheria, tetanus, pertussis (whole-cell vaccine) and poliomyelitis (inactivated vaccine)   Children
  Wongsaroj et al.[@R41]       Journal article    2013               Thailand                                    PVRV                                                                                                                                 Adults

HDCV: human diploid cell vaccine; N/A: not available; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.

Safety and immunogenicity in children
-------------------------------------

### Literature search

The search identified 11 studies on the safety and immunogenicity of pre-exposure prophylaxis in children aged 2 months to 15 years, including two published before 2007 ([Table 3](#T3){ref-type="table"}). All found it safe and immunogenic in both infants and children. Three found it safe and immunogenic for up to 5 years when given in combination with other childhood vaccines such as those against Japanese encephalitis, diphtheria, tetanus, pertussis and poliomyelitis (both oral and inactivated vaccines).[@R27]^,^[@R34]^,^[@R40]

###### Pre-exposure rabies prophylaxis in children, systematic review of the literature, 1989--2016

  Reference                                                       Age group (years)   Vaccine         Vaccination route              Regimen                                                  Antibody titre (IU/mL)^a^                        Comments                                                                        
  --------------------------------------------------------------- ------------------- --------------- ------------------------------ -------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lang et al.,[@R27] Vien et al.[@R40] and Lang et al.[@R26]^b^   \< 1                PVRV            Intramuscular                  2 doses at 2 and 4 months of age                         20.1                                             \> 1 (assessed after 5 years)                                                   Combined with vaccination against diphtheria, tetanus, pertussis and polio (inactivated vaccine)[@R27]^,^[@R40]
  Pengsaa et al.[@R34]                                            1--1.5              PCECV           Intramuscular or intradermal   1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28   15--41 (intramuscular); 4.1--8.5 (intradermal)   103--299 (intramuscular); 8.0--38 (intradermal) -- both assessed after 1 year   Combined with vaccination against Japanese encephalitis: antibody titres were higher following intramuscular than intradermal administration
  Lumbiganon et al.[@R31]^,b^                                     2--15               PCECV           Intramuscular or intradermal   1 dose on days 0, 7 and 28                               4.7--47                                          ND                                                                              Antibody titres were higher following intramuscular than intradermal administration
  Kamoltham et al.[@R21] and Kamoltham et al.[@R22]               5--8                PCECV           Intradermal                    1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28   \> 2                                             8.9--27.3 (assessed after ≥ 1 year)                                             All children had an antibody titre \> 0.5 IU/mL within 14 days of the booster dose, regardless of the time interval and the number of doses initially received
  Ravish et al.[@R35]                                             5--10               PCECV           Intradermal                    1 dose on days 0, 7 and 21                               ND                                               ND                                                                              80.4% of children completed treatment; there were no serious adverse reactions
  Shanbag et al.[@R36]                                            6--13               PVRV or PCECV   Intramuscular                  1 dose on days 0, 7 and 28                               12.2--14.5                                       ND                                                                              None
  Strady et al.[@R37]                                             12--79              HDCV or PVRV    Intramuscular                  1 dose on days 0, 7 and 28; or 1 dose on days 0 and 28   0.1--48 (assessed after 1 year)                  51 (3 doses); 13 (2 doses) -- both assessed after 1 year                        None
  Malerczyk et al.[@R32]                                          \< 15               PCECV           N/A                            N/A                                                      N/A                                              N/A                                                                             This review of \> 1200 children treated over \> 25 years concluded that the vaccine was safe and immunogenic, whether given intramuscularly or intradermally

HDCV: human diploid cell vaccine; N/A: not applicable; ND: not determined; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.

^a^ The values are either geometric means or ranges, as appropriate.

^b^ Although this study was published before 2007, it has been included because the results are still relevant.

High-risk settings
------------------

### Literature search

Pre-exposure prophylaxis programmes for high-risk populations, and especially children, were strongly recommended in reports of expert meetings on rabies and child health in Asia and the Middle East.[@R6]^,^[@R13]^,^[@R19] In India, the Academy of Pediatrics called for its inclusion in the immunization schedule for high-risk children younger than 18 years.[@R39]

### Peru

In 2011, pre-exposure prophylaxis was administered in 286 localities in the Amazonas Region: 86% were in Condorcanqui Province and 14% were in Bagua Province. In total, 13 986 people were immunized. In these areas, the number of rabies deaths dropped from 13 in 2010 and 20 in 2011 to zero child deaths and only two adult deaths (both had refused vaccination) in 2012.[@R6] [Fig. 2](#F2){ref-type="fig"} shows the number of human rabies deaths in Bagua and Condorcanqui Provinces between 1975 and 2015. The number of reported bat bites, which is used as a surrogate for rabies exposure, decreased between 2010 and 2013 ([Table 4](#T4){ref-type="table"}) but there was no change in the risk factors for bites, such as the number of houses bats could enter. In areas adjacent to the Amazonas Region, in which pre-exposure prophylaxis was not implemented, there were outbreaks of human rabies in 2011, 2013 and 2015 (unpublished data, 2015). The programme was extended until 2015 to cover an additional 423 communities in Bagua and Condorcanqui Provinces at a high risk of rabies. By 2015, 71 400 people in the Amazonas Region (i.e. 86% of the population) had received pre-exposure prophylaxis and, by the end of 2014, 121 285 people (i.e. 76% of the target population) in Cusco, Junín and Loreto Regions had also received it. No serious adverse events were reported.

![**Human rabies deaths, Amazonas Region, Peru, 1975--2015**](BLT.16.173039-F2){#F2}

###### Bat bites by region, Peru, 2009--2013[@R6]

  Region     No. of bat bites reported   \% of all reported bat bites                                    
  ---------- --------------------------- ------------------------------ ------- ------- ------- -------- -------
  Amazonas   1 576                       5 714                          2 145   1 733   833     12 001   59.2
  Cusco      50                          169                            36      441     20      716      3.5
  Loreto     1 122                       856                            1 458   1 380   590     5 406    26.7
  Junin      119                         415                            179     142     29      884      4.4
  Others     465                         224                            295     229     41      1 254    6.2
  All        3 332                       7 378                          4 113   3 925   1 513   20 261   100.0

### Philippines

By April 2010, the routine pre-exposure prophylaxis immunization programme had achieved an average coverage of 47.25% in the target population: 21 637 high-risk children in 31 schools in seven regions were immunized (unpublished data, 2010). In the town of Cabusao, 188 schoolchildren received at least one vaccine dose (i.e. 86% of those eligible) and 90% of the 188 completed the pre-exposure prophylaxis regimen. Subsequently, 3.5% received postexposure prophylaxis within 3 years following suspected exposure. The programme was stopped in 2011 because a large increase in rabies exposure led to a vaccine shortage and priority was given to the immunization of people involved in canine vaccination campaigns. Pre-exposure prophylaxis of schoolchildren was planned to restart in 2016.

Cost--effectiveness
-------------------

### Literature search

Few recent studies have assessed the cost--effectiveness of pre-exposure rabies prophylaxis. One study estimated the annual global direct cost of administering postexposure rabies prophylaxis at 1.7 billion United States dollars (US\$), plus an additional US\$ 1.3 billion in lost income.[@R1] In a cost assessment of pre-exposure prophylaxis, researchers showed that it would be cost-neutral if 1% of children were exposed to rabies each year and if the price of the vaccine did not exceed US\$ 1.32 per dose, once the cost of postexposure prophylaxis boosters required after exposure was taken into account.[@R30] The acceptable vaccine cost increased in proportion to the incidence of rabies. In a Thai study, the estimated cost of pre-exposure prophylaxis for children ranged from US\$ 2.00 to 7.25 per child depending on the schedule and vaccine used: there was an additional cost of US\$ 18.00 to 23.50 per child if postexposure prophylaxis was required later.[@R17] Pre-exposure prophylaxis became cost-comparable to the least expensive postexposure schedule (i.e. intradermal immunization without rabies immunoglobulin) when the annual risk of a dog bite was approximately 23%. If equine or human rabies immunoglobulin was used with postexposure vaccines, pre-exposure prophylaxis was cost-comparable when the annual risk of a dog bite was 7% or 3%, respectively. As over 30% of Thai children had been bitten by a dog by the age of 15 years, it was estimated that the actual incidence of dog bites in the population of central Thailand was only 2.3% per year. Consequently, pre-exposure prophylaxis with currently licensed vaccines would not be cost-effective in this setting.

### Peru

The cost of the mass pre-exposure prophylaxis campaign was estimated to be US\$ 4 111 000, of which US\$ 3 560 000 was the cost of the vaccine. The average cost per immunized person was US\$ 69. By assuming that the risk of rabies was constant (i.e. the rabies virus remained in circulation and the risk of a bat bite was unchanged) and that, each year, rabies caused 20 deaths per 50 000 people in Condorcanqui Province without pre-exposure prophylaxis, we estimated the cost of pre-exposure prophylaxis to be US\$ 205 000 per life saved after the first year.[@R6] After 5 years, the cost decreased to US\$ 41 000 per life saved. This amount is comparable to the cost of treating one rabies-infected individual, including the cost of transport, laboratory diagnosis and hospitalization. The use of intradermal vaccinations would reduce the vaccination cost by 80%. However, intramuscular vaccination continues to be used in Peru because: (i) there is no shortage of rabies vaccine in the country; (ii) staff have not been trained in the multiple uses of rabies vaccine vials for intradermal administration; and (iii) the national authorities elected to use the intramuscular route to minimize the risk of errors in vaccine administration.

### Philippines

Pre-exposure prophylaxis with three doses of purified Vero cell or chick embryo cell vaccine was estimated to cost US\$ 4.77 per patient (unpublished data, 2015; ([Table 5](#T5){ref-type="table"}). For a patient weighing between 26 and 50 kg, pre-exposure prophylaxis reduced the cost of postexposure prophylaxis by up to 38% following category-II exposure (i.e. "nibbling of uncovered skin, minor scratches or abrasions without bleeding")[@R5] and by up to 85% following category-III exposure (i.e. "single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats"),[@R5] after the cost of pre-exposure prophylaxis was taken into account.

###### Cost of postexposure rabies prophylaxis, the Philippines, 2007

  Exposure category^a^   Cost in US\$ per patient (treatment specifics)                                                                                                                                        Savings per patient (weight range: 26--50 kg) who had pre-exposure prophylaxis           
  ---------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ------- ----
  Category II            3.19 (2 intradermal doses of PCECV or PVRV at US\$ 1.59 per dose; no RIG)   12.76 (8 intradermal doses of PCECV or PVRV at US\$ 1.59 per dose; no RIG)                                                                                                                 4.80    38
  Category III           3.19 (2 intradermal doses of PCECV or PVRV at US\$ 1.59 per dose; no RIG)   51.76 (8 intradermal doses PCECV or PVRV at US\$ 1.59 per dose; 2 vials of ERIG at US\$ 19.52 per vial)                                                                                    43.80   85

ERIG: equine rabies immunoglobulin; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine; RIG: rabies immunoglobulin; US\$: United States dollar.

^a^ Category-II exposure is defined as nibbling of uncovered skin, minor scratches or abrasions without bleeding and category-III exposure, as single or multiple transdermal bites or scratches, contamination of mucous membranes with saliva from licks, licks on broken skin, exposures to bats.[@R5]

Notes: The percentage saving is the cost saving divided by the cost of postexposure prophylaxis in a patient who did not have pre-exposure prophylaxis × 100. Prices were converted at a rate of US\$ 1 per 47.65 Philippine pesos. The cost of postexposure rabies prophylaxis was the cost at bite centres taking part in a national pre-exposure rabies prophylaxis programme for high-risk populations, which was lower than in hospitals and private bite centres. The cost of pre-exposure rabies prophylaxis was US\$ 4.77 per patient (US\$ 1.59 per intradermal dose × 3). In calculating savings, the cost of pre-exposure prophylaxis was taken into account.

Accelerated or revised regimens
-------------------------------

Nine studies investigated the safety and immunogenicity of an accelerated or revised pre-exposure prophylaxis regimen ([Table 6](#T6){ref-type="table"}; available at <http://www.who.int/bulletin/volume/95/03/16-173039>). Administering all vaccine doses within 1 week[@R22]^,^[@R23]^,^[@R28]^,^[@R33] or in one[@R23]^,^[@R24] or two visits[@R41] elicited an adequate antibody titre of 0.5 IU/mL or higher for up to 1 year,[@R23]^--^[@R25]^,^[@R28]^,^[@R33] even when given in combination with Japanese encephalitis vaccine.[@R20] Adequate titres were observed in people who received a total dose of at least 2 IU of intradermal pre-exposure prophylaxis.[@R15] Factors associated with an inadequate antibody titre included: (i) a period of more than 21 days between the first and third doses; (ii) male sex; (iii) vaccine type or manufacturer; and (iv) a body mass index of 25 kg/m^2^ or higher.[@R14]

###### Accelerated or revised pre-exposure rabies prophylaxis, systematic review of the literature, 2007--2016

  Reference                                         Study type                                       No. of study participants   Vaccine               Vaccination route               Regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Antibody titre (IU/mL)                                                                                                                                                    Comments                                                                                                                                                                                                                                              
  ------------------------------------------------- ------------------------------------------------ --------------------------- --------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Kamoltham et al.[@R22]                            Randomized, open-label phase-II clinical trial   703                         PCECV                 Intradermal                     (i) 0.1 mL on days 0 and 28; and (ii) 0.1 mL on days 0, 7 and 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ND                                                                                                                                                                        \(i\) 10.76 (GMT; range: 1.87--37); and (ii) 22.12 (GMT; range: 2.13--199) -- both measured 14 days after receiving 0.1 mL PCECV booster vaccination on days 365 and 368                                                                              Seroconversion^a^ occurred within 14 days of booster vaccination in all vaccinees who received two or three doses of pre-exposure prophylaxis
  Khawplod et al.[@R25] and Khawplod et al.[@R23]   Randomized, prospective                          96 and 52                   PVRV and PCECV        Intradermal and intramuscular   (i) 0.1 mL PVRV intradermally at two sites on days 0, 7 and 28; (ii) 0.1 mL PVRV intradermally at two sites on days 0, 3 and 7; (iii) 1.0 mL PVRV intramuscularly at one site on days 0, 3 and 7; (iv) 0.1 mL PVRV intradermally at two sites on day 0; (v) 0.1 mL PVRV intradermally at two sites on days 0, 3 and 7 and at one site on days 28 and 90; and (vi) 0.1 mL PCECV intradermally at two sites on days 0, 3 and 7 and at one site on days 28 and 90                                                                                                                                                                                                                           (i) 0.96 (GMT) on day 360; (ii) 1.12 (GMT) on day 360; (iii) 0.97 (GMT) on day 360; (iv) 0.41 (GMT) on day 360; (v) 5.84 (GMT) on day 28; and (vi) 5.96 (GMT) on day 28   (i) 49.39 (GMT) on day 374; (ii) 105.08 (GMT) on day 374; (iii) 125.00 (GMT) on day 374; (iv) 51.96 (GMT) on day 374; (v) ND; and (vi) ND -- all measured after booster vaccination with 0.1 mL PVRV intradermally at two sites on days 360 and 363   Seroconversion^a^ occurred after booster vaccination with all regimens; the two studies used the same regimens and reported the same data
  Mills et al.[@R33]                                Case series                                      420                         HDCV                  Intradermal                     0.1 mL at two sites on days 0 and 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \> 0.5 in 94.5% of vaccinees on day 28                                                                                                                                    ND                                                                                                                                                                                                                                                    Seroconversion^a^ occurred in 94.5% of vaccinees by day 28 following a two-visit pre-exposure prophylaxis regimen
  Khawplod et al.[@R24]                             Abbreviated, prospective                         109                         PCECV                 Intradermal and intramuscular   (i) 0.1 mL intradermally on days 0, 7 and 21, followed by a 1.0-mL intramuscular booster on days 360 and 363; (ii) 0.1 mL intradermally on days 0, 7 and 21, followed by a 0.1-mL intradermal booster at four sites on day 360; (iii) 0.1 mL intradermally at two sites on day 0, followed by a 1.0-mL intramuscular booster on days 360 and 363; (iv) 0.1 mL intradermally at two sites on day 0, followed by a 0.1-mL intradermal booster at four sites on day 360; (v) 1.0 mL intramuscularly on day 0, followed by a 1.0-mL intramuscular booster on days 360 and 363; and (vi) 1.0 mL intramuscularly on day 0, followed by a 0.1-mL intradermal booster at four sites on day 360   (i) 0.49 (NAb); (ii) 0.30 (NAb); (iii) 0.15 (NAb); (iv) 0.10 (NAb); (v) 0.08 (NAb); and  (vi) 0.11 (NAb) -- all measured before booster vaccination on day 360            (i) 11.27 (NAb); (ii) 42.49 (NAb); (iii) 9.71 (NAb); (iv) 11.96 (NAb); (vi) 10.13 (NAb); and  (vi) 13.33 (NAb) -- all measured 7 days after booster vaccination                                                                                       Seroconversion^a^ occurred within 7 days of booster vaccination for all regimens assessed
  Lau & Hohl[@R28]                                  Case series                                      54                          PCECV                 Intradermal                     0.1 mL at two sites on days 0 and 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      \> 0.5 in 94.4% of vaccinees on day 28                                                                                                                                    ND                                                                                                                                                                                                                                                    Seroconversion^a^ occurred in 94.4% of vaccinees by day 28
  Wongsaroj et al.[@R41]                            Randomized, prospective                          55                          PVRV                  Intradermal and intramuscular   (i) 0.1 mL intradermally at two sites on days 0 and 21; and (ii) 0.5 mL intramuscularly on days 0, 7 and 21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              (i) 4.51 (NAb); and (ii) 6.74 (NAb) -- both measured on day 35                                                                                                            (i) 14.38 (GMT); and (ii) 14.06 (GMT) -- both measured 14 days after booster vaccination with 0.1 mL PVRV intradermally on days 360 and 363                                                                                                           Seroconversion^a^ occurred within 14 days of booster vaccination with both regimens
  Jelinek[@R20]                                     Randomized, observer-blinded, multicentre        661                         PCECV                 Intramuscular                   (i) 1.0 mL on days 0, 7 and 28, with standard Japanese encephalitis vaccine regimen; (ii) 1.0 mL on days 0, 3 and 7, with accelerated Japanese encephalitis vaccine regimen; and (iii) 1.0 mL PCECV alone on days 0, 7 and 28                                                                                                                                                                                                                                                                                                                                                                                                                                                            \> 0.5 in 97--100% of vaccinees on day 57                                                                                                                                 ND                                                                                                                                                                                                                                                    Seroconversion^a^ occurred in 97--100% of vaccinees by day 57
  Brown et al.[@R15]                                Cohort study                                     12                          PVRV (booster dose)   Intradermal                     People with an antibody titre \< 0.5 IU/mL following initial pre-exposure prophylaxis received one booster dose after 2 years to give a total vaccine dose ≥ 2 IU                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0.18 (mean) before booster                                                                                                                                                17.33 (mean) after booster                                                                                                                                                                                                                            Seroconversion^a^ occurred in all vaccinees who received ≥ 2 IU of vaccine

HDCV: human diploid cell vaccine; GMT: geometric mean titre; NAb: neutralizing antibody; ND: not determined; PCECV: purified chick embryo cell vaccine; PVRV: purified Vero cell rabies vaccine.

^a^ Seroconversion was defined as an antibody titre \> 0.5 IU/mL.

Booster vaccinations
--------------------

Four studies investigated recommendations on booster vaccines ([Table 7](#T7){ref-type="table"}; available at <http://www.who.int/bulletin/volume/95/03/16-173039>). They concluded that: (i) the interval between booster vaccinations could be extended by up to 10 years;[@R16] (ii) serological surveillance or booster vaccination after 1 year is advisable for people in high-risk occupations;[@R29] (iii) serological testing after the third intramuscular or intradermal pre-exposure prophylaxis dose is unnecessary;[@R18] and (iv) healthy subjects may not require postexposure prophylaxis boosters on re-exposure to rabies for up to 3 months after pre-exposure or previous postexposure prophylaxis.[@R38]

###### Booster rabies vaccination recommendations, systematic review of the literature, 2007--2016

  Reference                         Study type                    No. of participants   Vaccination regimen                                                                                                  Antibody titre (IU/mL)                                                                                                        Conclusion
  --------------------------------- ----------------------------- --------------------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Brown et al.[@R16]                Retrospective cohort study    89                    Intradermal pre-exposure prophylaxis                                                                                 ≥ 0.5 after a mean of 5 years (range: 1--12) in 100% of vaccinees who received ≥ 0.6 mL of vaccine over two or three visits   Intradermal pre-exposure prophylaxis with 0.6 mL of vaccine over three visits could extend the interval before booster vaccination to 10 years
  Lim & Barkham,[@R29] Cohort 1     Retrospective cohort study    66                    Three doses of PVRV pre-exposure prophylaxis                                                                         \> 0.5 in 60.6% of vaccinees after 1 year                                                                                     Serological surveillance or a booster vaccination 1 year after primary pre-exposure prophylaxis is advised for people in high-risk occupations
  Lim & Barkham,[@R29] Cohort 2     Retrospective cohort study    15                    Four doses: three of pre-exposure prophylaxis and one booster dose given after a median of 10 years (range: 3--18)   \> 0.5 in 100% of vaccinees after a median of 10 years (range: 3--18)                                                         Serological surveillance or a booster vaccination 1 year after primary pre-exposure prophylaxis is advised for people in high-risk occupations
  Cunha et al.,[@R18] Group 1       Randomized controlled study   65                    Intradermal pre-exposure prophylaxis                                                                                 \> 0.5 in 97% of vaccinees after a mean of 10 days and \> 0.5 in 20--25% after a mean of 180 days                             Serological testing after the third dose of pre-exposure prophylaxis is unnecessary^a^
  Cunha et al.,[@R18] Group 2       Randomized controlled study   62                    Intramuscular pre-exposure prophylaxis                                                                               \> 0.5 in 100% of vaccinees after a mean of 10 days and \> 0.5 in 63--65% after a mean of 180 days                            Serological testing after the third dose of pre-exposure prophylaxis is unnecessary^a^
  Sudarshan et al.,[@R38] Group 1   Literature review             577                   Pre-exposure prophylaxis                                                                                             \> 0.5 in 100% after a mean of 3 months                                                                                       It may be safe not to administer postexposure prophylaxis in healthy individuals re-exposed to rabies within 3 months of pre-exposure or previous postexposure prophylaxis
  Sudarshan et al.,[@R38] Group 2   Literature review             2795                  Postexposure prophylaxis                                                                                             \> 0.5 in 99.9% after a mean of 3 months                                                                                      It may be safe not to administer postexposure prophylaxis in healthy individuals re-exposed to rabies within 3 months of pre-exposure or previous postexposure prophylaxis

PVRV: purified Vero cell rabies vaccine.

^a^ This study did not follow up study participants 1 year after pre-exposure prophylaxis or simulate responses to postexposure prophylaxis.

Discussion
==========

Several studies demonstrated that pre-exposure rabies prophylaxis was safe and immunogenic in children and could be co-administered with other childhood vaccines.[@R21]^,^[@R22]^,^[@R27]^,^[@R32]^,^[@R34]^--^[@R37]^,^[@R40] In addition, it could be given with the Japanese encephalitis vaccine in both adults and children. In most African countries pre-exposure rabies prophylaxis is unlikely to be included in the expanded programme on immunization because of competing priorities and because postexposure prophylaxis would still be required following suspected contact. Nevertheless, expert consultations advocate vaccination for people in remote, high-risk areas[@R6]^,^[@R19]^,^[@R36] and national pre-exposure prophylaxis programmes have been implemented in Peru and the Philippines.[@R6]^,^[@R7] In Peru, the programme was successful in preventing child deaths due to bat rabies in high-risk areas, which demonstrates the value of targeted pre-exposure prophylaxis in places where controlling disease in the animal reservoir is challenging.[@R11] Although it can be difficult for individuals to recall the date of pre-exposure prophylaxis, this does not undermine its usefulness for saving human lives in situations where exposure is uncertain or there is limited access to biologicals. Vaccination certificates are often treasured and kept safe and, in Peru, the identification and recording of vaccinated individuals has improved nationally.

Pre-exposure rabies prophylaxis is also associated with cost savings because fewer postexposure vaccinations and no rabies immunoglobulin are required following suspected exposure. However, the few studies that assessed costs suggest that community vaccination at current vaccine and delivery costs would not be cost-effective in most situations.[@R1]^,^[@R17]^,^[@R30]^,^[@R42]^,^[@R43] Preliminary studies on accelerated or revised regimens indicate that 1-week or even single-day regimens may be as effective as the recommended 3- to 4-week regimen: shorter treatment and fewer doses would make treatment simpler and less expensive.

The development of a more immunogenic rabies vaccine that provides life-long immunological memory with a single dose and that can be preserved at ambient temperatures, thereby eliminating the need for a cold chain, would make pre-exposure prophylaxis simpler and more cost-effective. The ideal vaccine would induce an antibody titre that remained above 0.5 IU/mL for decades and would protect people who fail to receive prompt booster immunization following exposure. In animal studies, attempts have been made to increase the current vaccine's immunogenicity using adjuvants,[@R44]^,^[@R45] genetic manipulation,[@R46] adenovirus vectors derived from chimpanzee viruses[@R47] and attenuated measles viruses,[@R48]^,^[@R49] which would enable combined early childhood immunization against both measles and rabies.

Although pre-exposure prophylaxis using currently available biologicals may not be cost-effective in general, we believe it could be beneficial in: (i) remote communities where access to postexposure prophylaxis and rabies immunoglobulin is often delayed or nonexistent; (ii) situations in which the risk of exposure is high and may go unrecognized, for example, in young children or people exposed occupationally, such as veterinarians; or (iii) places where controlling rabies in the animal reservoir is difficult and the risk of human exposure is high, such as in the Amazon basin where bat rabies is endemic. It is important that staff involved in canine rabies control receive pre-exposure prophylaxis because of their higher risk of exposure. Currently, serological surveillance and booster vaccinations are recommended only for people at an occupational risk.[@R5] Controlling canine rabies remains the cornerstone of preventing human rabies deaths. Pre-exposure prophylaxis should not distract from canine vaccination efforts, the provision of postexposure prophylaxis and education to raise local awareness of rabies. In high-risk areas, pre-exposure prophylaxis should be included in the expanded programme on immunization in children from 1 year of age,[@R5] followed by a booster after 1 year. Vaccination should be documented with a certificate and any available medical records should be updated. Targeted, mass campaigns in remote, high-incidence areas should be considered to provide protection for both children and adults and travel recommendations should be provided for newcomers. Accelerated vaccination regimes and novel vaccines that provide life-long immunity with a single dose and are stable at ambient temperatures would make pre-exposure prophylaxis more cost-effective and easier to implement.
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